Platelet glycoprotein IIb/IIIa inhibition in acute coronary syndromes: Gradient of benefit related to the revascularization strategy.
Proceedings of the National Academy of Sciences of the United States of America.
Times cited: 129
One-year survival following early revascularization for cardiogenic shock.
JAMA - Journal of the American Medical Association.
Times cited: 456
Roundtable panel discussion: The role of glycoprotein IIb-IIIa receptor inhibitors in acute ischemic coronary syndromes.
Journal of the American College of Cardiology.
Times cited: 2